SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-244953
Filing Date
2019-09-13
Accepted
2019-09-13 17:05:40
Documents
13
Period of Report
2019-09-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d800689d8k.htm   iXBRL 8-K 53827
2 EX-10.1 d800689dex101.htm EX-10.1 228183
  Complete submission text file 0001193125-19-244953.txt   463861

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20190910.xsd EX-101.SCH 3079
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20190910_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20190910_pre.xml EX-101.PRE 11414
12 EXTRACTED XBRL INSTANCE DOCUMENT d800689d8k_htm.xml XML 3420
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 191093159
SIC: 2836 Biological Products, (No Diagnostic Substances)